Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Real-time 3D ultrasound imaging with a clip-on device attached to common 1D array transducers
Li, Shuangliang , Zou, Jun , Dong, Zhijie , Huang, Chengwu , Lowerison, Matthew R. , Yan, Dongliang, Wang, Yike , Chen, Shigao , Song, Pengfei

Mayo Clinic

The Journal of the Acoustical Society of America | July 3, 2024 | Volume: 155 | Issue: 3_Supplement | Pages: A102-A102

10.1121/10.0026955 Get It

Performing 3D ultrasound imaging at a real-time volume rate (e.g., >20 Hz) is a challenging task. While 2D array transducers remain the most practical approach for real-time 3D imaging, the large number of transducer elements (e.g., several thousand) that are necessary to cover an effective 3D field-of-view impose a fundamental constraint on imaging speed. Although solutions such as multiplexing and specialized transducers, including sparse arrays and row-column-addressing arrays, have been developed to address this limitation, they inevitably compromise imaging quality (e.g., SNR, resolution) in favor of speed. Coupled with the high equipment cost of 2D arrays, these compromises hinder the widespread adoption of 3D ultrasound imaging technologies in clinical settings. In this presentation, we introduce an innovative transducer clip-on device comprising a water-immersible, fast-tilting electromechanical acoustic reflector and a redirecting reflector to enable real-time 3D ultrasound imaging using common 1D array transducers. We will first introduce the principles underlying our novel technique, followed by validation studies incorporating simulation and experimental data. We will also demonstrate the feasibility of using the clip-on device to achieve a high 3D imaging volume rate that is suitable for advanced imaging modes such as shear wave elastography, blood flow imaging, and super-resolution ultrasound localization microscopy.
Endoscopic‐assisted transorbital extended orbital exenteration: A multi‐institutional preclinical study
Roccuzzo, Giuseppe , Vyskocil, Erich , Kandathil, Sam Augustine , Peris‐Celda, Maria , Leong, Samuel , Herman, Philippe , Vérillaud, Benjamin , Bresson, Damien, Schreiber, Alberto , Arosio, Alberto Daniele , Valentini, Marco , Pozzi, Fabio , Volpi, Luca , Nicolai, Piero , Ferrari, Marco , Kandathil, Sam Augustine , Borsetto, Daniele , Taboni, Stefano , Mattavelli, Davide , Ferrari, Marco , Schreiber, Alberto , Hirtler, Lena , Agosti, Edoardo , Kuan, Edward C , Wang, Eric W , Sharma, Rishi , Vinciguerra, Alessandro , Bresson, Damien , Erović, Boban M. , Vural, Alperen , Dallan, Iacopo , Doglietto, Francesco , Mattavelli, Davide , Rampinelli, Vittorio , Battaglia, Paolo , Turri‐Zanoni, Mario , Bignami, Maurizio , Castelnuovo, Paolo

Mayo Clinic

Head & Neck | July 3, 2024 | Volume: 46 | Issue: 9 | Pages: 2327-2339

10.1002/hed.27858 | PMID 38958177 Get It

Abstract Background Sinonasal malignancies with orbital invasion have dismal prognosis even when treated with orbital exenteration (OE). Sugawara et al. developed a surgical strategy called “extended‐OE (EOE),” showing encouraging outcomes. We hypothesized that a similar resection is achievable under endoscopic guidance through the exenterated orbit (endoscopic‐EOE). Methods The study was conducted in three institutions: University of Vienna; Mayo Clinic; University of Insubria; 48 orbital dissections were performed. A questionnaire was developed to evaluate feasibility and safety of each step, scoring from 1 to 10, (“impossible” to “easy,” and “high risk” to “low risk,” respectively), most likely complication(s) were hypothesized. Results The step‐by‐step technique is thoroughly described. The questionnaire was answered by 25 anterior skull base surgeons from six countries. Mean, median, range, and interquartile range of both feasibility and safety scores are reported. Conclusions Endoscopic‐EOE is a challenging but feasible procedure. Clinical validation is required to assess real‐life outcomes.
STAGER checklist: Standardized testing and assessment guidelines for evaluating generative artificial intelligence reliability
Chen, Jinghong , Zhu, Lingxuan , Zeng, Dongqiang , Qi, Chang , Tang, Bufu , Shi, Wenjie , Guo, Shipeng, Sun, Xu , Ngo, Trunghieu, Pu, Zhongji , He, Yongbin, Wu, Haiyang , Cheungpasitporn, Wisit, Huang, Haojie , Wang, Shixiang , Cabannes, Loïc, Ren, Gerald Sng Gui , Ali, Stephen R , Cheng, Quan, Miao, Kai , Mou, Weiming , Lin, Anqi , Zeng, Dongqiang, Liu, Zaoqu , Jiang, Aimin , Shi, Wenjie, Kahlert, Ulf D. , Zhou, Jian‐Guo , Lu, Xiaofan , Jia, Baolei , Jeon, Che Ok , Gu, Shuqin , Cheungpasitporn, Wisit , Mao, Weipu , Chen, Xin , Cabannes, Loïc, Whitaker, Iain Stuart , Cheng, Quan, Yuan, Shuofeng , Luo, Peng

Mayo Clinic

iMetaOmics | July 2, 2024 | Volume: 1 | Issue: 1 | Pages: No page available

10.1002/imo2.7 | PMID 41675544 Get It

Abstract Generative artificial intelligence (AI) holds immense potential for medical applications, but the lack of a comprehensive evaluation framework and methodological deficiencies in existing studies hinder its effective implementation. Standardized assessment guidelines are crucial for ensuring reliable and consistent evaluation of generative AI in healthcare. Our objective is to develop robust, standardized guidelines tailored for evaluating generative AI performance in medical contexts. Through a rigorous literature review utilizing the Web of Sciences, Cochrane Library, PubMed, and Google Scholar, we focused on research testing generative AI capabilities in medicine. Our multidisciplinary team of experts conducted discussion sessions to develop a comprehensive 32‐item checklist. This checklist encompasses critical evaluation aspects of generative AI in medical applications, addressing key dimensions such as question collection, querying methodologies, and assessment techniques. The checklist and its broader assessment framework provide a holistic evaluation of AI systems, delineating a clear pathway from question gathering to result assessment. It guides researchers through potential challenges and pitfalls, enhancing research quality and reporting and aiding the evolution of generative AI in medicine and life sciences. Our framework furnishes a standardized, systematic approach for testing generative AI's applicability in medicine. For a concise checklist, please refer to Table S or visit GenAIMed.org .
Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: An adverse event (AE)-based analysis.
Munir, Tahla, Mohseninejad, Leyla, Srivastava, Tushar , Gupta, Anurag , Gautam, Raju, Challagulla, Swetha, Mei, Xue , Yang, Keri, Williams, Rhys , Wang, Yucai , Xue, Mei, Williams, Rhys , Lévy, Vincent , Zhou, Shouhao

Mayo Clinic

Journal of Clinical Oncology | July 2, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e19049-e19049

10.1200/jco.2024.42.16_suppl.e19049 Get It

e19049 Background: Acala and zanu are 2nd generation Bruton tyrosine kinase inhibitors (BTKis) that have demonstrated improved safety profiles vs 1st generation BTKi ibrutinib in clinical trials. While head-to-head comparison of zanu vs acala is lacking, a recent meta-analysis of clinical trials provided a comprehensive, indirect comparison of the AE profiles in B-cell malignancies (Hwang, Hemasphere. 2023;7(S3):1134). This study aims to evaluate costs and impacts on quality of life (QoL) for zanu vs acala using their AE profiles. Methods: A health economic model was developed to determine cost and QoL associated with AE management for zanu and acala. The incidence rates ( IRs) of all grade and grade ≥3 AEs of interest (n=21, including bleeding events, hypertension, atrial fibrillation, cytopenias, infections, headache, arthralgia, diarrhea) were taken from the meta-analysis. Additional model inputs, such as disutility, average duration of AE, and unit cost of each AE were sourced from published literature and publicly available cost databases in consultation with clinical experts. The model was developed from the US perspective, considering Medicare costs, inflated to 2023 USD. Model outcomes were AE management cost (= IR * unit cost) and quality-adjusted life years (QALYs) lost due to AE (= IR * Disutility * Duration/365.25). Results: In the base-case scenario (considering all AEs), treating a hypothetical cohort of 1000 patients (pts) with zanu instead of acala yielded cost savings of $124K and 3.7 QALY gains (i.e., 3.7 years extra in full health). Subgroup analysis for severe (grade ≥3) and non-severe AEs (grade 1-2) demonstrated similar trends. A sensitivity analysis limited to AEs significantly different between zanu and acala (n=13) yielded consistent results. Additionally, a probabilistic sensitivity analysis, conducted with 1000 iterations to account for uncertainty in model parameters, confirmed robustness of the model, indicating stable conclusions across a wide range of parameter uncertainties. Conclusions: This analysis suggested that zanu is cost-saving and associated with added health benefits compared to acala in terms of AE management in pts with B-cell malignancies. Should these results derived from meta-analysis of clinical trial data be applicable to real-world pt populations across different indications, the potential cost savings could be considerable. These results could be further improved if the differences in efficacy of zanu vs acala are also incorporated. [Table: see text]
Cerebrovascular reactivity MRI as a biomarker for cerebral small vessel disease–related cognitive decline: Multi‐site validation in the MarkVCID Consortium
Liu, Peiying , Hazel, Kaisha , Pottanat, George , Xu, Cuimei, Pillai, Jay J. , Lucke, Emma, Bauer, Christopher E. , Gold, Brian T. , Greenberg, Steven M. , Helmer, Karl G. , Jann, Kay , Kramer, Joel H. , Maillard, Pauline , Mulavelil, Rachel, Rodriguez, Pavel, Seshadri, Sudha , Singh, Herpreet , Dediós, Angel Gabriel Velarde, Kalyani, Rita R. , Rosenberg, Paul B. , Yaşar, Sevil , Albert, Marilyn , Lu, Hanzhang , Lu, Hanzhang , Seshadri, Sudha , Pillai, Jay J , Liu, Peiying , Maillard, Pauline , Lin, Zixuan , Jiang, Dengrong , Jicha, Gregory A. , Satizábal, Claudia L. , Schwab, Kristin , Wang, Danny J.J. , Moghekar, Abhay

Mayo Clinic

Alzheimer's & Dementia | July 1, 2024 | Volume: 20 | Issue: 8 | Pages: 5281-5289

10.1002/alz.13888 | PMID 38951718 Get It

Abstract INTRODUCTION Vascular contributions to cognitive impairment and dementia (VCID) represent a major factor in cognitive decline in older adults. The present study examined the relationship between cerebrovascular reactivity (CVR) measured by magnetic resonance imaging (MRI) and cognitive function in a multi‐site study, using a predefined hypothesis. METHODS We conducted the study in a total of three analysis sites and 263 subjects. Each site performed an identical CVR MRI procedure using 5% carbon dioxide inhalation. A global cognitive measure of Montreal Cognitive Assessment (MoCA) and an executive function measure of item response theory (IRT) score were used as outcomes. RESULTS CVR and MoCA were positively associated, and this relationship was reproduced at all analysis sites. CVR was found to be positively associated with executive function. DISCUSSION The predefined hypothesis on the association between CVR and a global cognitive score was validated in three independent analysis sites, providing support for CVR as a biomarker in VCID. Highlights This study measured a novel functional index of small arteries referred to as cerebrovascular reactivity (CVR). CVR was positively associated with global cognition in older adults. This finding was observed in three independent cohorts at three sites. Our statistical analysis plan was predefined before beginning data collection.
UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long‐Established Target Mitochondrial Pyruvate Carrier
Ran, Linyu, Chen, Miao , Ye, Jihui , Zhang, Song , Luo, Zhibing , Bai, Tengfei, Qian, Chenchen , Shan, Mengtian, Chu, Yong , Herrmann, Joerg , Wang, Feilong , Wang, Feilong , Ran, Linyu, Zhou, Quan , Li, Qiang

Mayo Clinic

Advanced Science | July 1, 2024 | Volume: 11 | Issue: 33 | Pages: No page available

10.1002/advs.202307224 | PMID 38946607 Get It

AbstractTargeting NLRP3 inflammasome has been recognized as a promising therapeutic strategy for the treatment of numerous common diseases. UK5099, a long‐established inhibitor of mitochondrial pyruvate carrier (MPC), is previously found to inhibit macrophage inflammatory responses independent of MPC expression. However, the mechanisms by which UK5099 inhibit inflammatory responses remain unclear. Here, it is shown that UK5099 is a potent inhibitor of the NLRP3 inflammasome in both mouse and human primary macrophages. UK5099 selectively suppresses the activation of the NLRP3 but not the NLRC4 or AIM2 inflammasomes. Of note, UK5099 retains activities on NLRP3 in macrophages devoid of MPC expression, indicating this inhibitory effect is MPC‐independent. Mechanistically, UK5099 abrogates mitochondria‐NLRP3 interaction and in turn inhibits the assembly of the NLRP3 inflammasome. Further, a single dose of UK5099 persistently reduces IL‐1β production in an endotoxemia mouse model. Importantly, structure modification reveals that the inhibitory activities of UK5099 on NLRP3 are unrelated to the existence of the activated double bond within the UK5099 molecule. Thus, this study uncovers a previously unknown molecular target for UK5099, which not only offers a new candidate for the treatment of NLRP3‐driven diseases but also confounds its use as an MPC inhibitor in immunometabolism studies.
Association between hemoglobin (Hb) improvement and patient-reported outcomes (PROs) in patients (pts) with myelofibrosis (MF) and anemia: Post hoc pooled analysis of momelotinib (MMB) phase 3 trials.
Palmer, Jeanne , Mazerolle, Flora , Liu, Tom, M’Hari, Manal, Regnault, Antoine , Zhang, Shiyuan , Cardellino, Anna, Strouse, Bryan, Sahni, Jasmine, Wang, Zhaohui , LeBlanc, Thomas W.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 6574-6574

10.1200/jco.2024.42.16_suppl.6574 Get It

6574 Background: Pts with MF experience debilitating symptoms that negatively impact health-related quality of life (HRQOL), a burden compounded in those with anemia. Prior analysis of the phase 3 SIMPLIFY-1 (S1) and SIMPLIFY-2 (S2) trials found that achieving transfusion independence at wk 24 was associated with improved PROs, but the association of anemia severity by Hb level with PROs was inconclusive (Mesa, ASCO 2023, Poster 7066). This new post hoc analysis explored the impact of Hb improvement on PROs in pts with MF and anemia. Methods: The pooled treatment-agnostic analysis set included pts with anemia (baseline [BL] Hb <10 g/dL) from 3 phase 3 trials: S1 (JAK inhibitor [JAKi] naive; MMB vs ruxolitinib), S2 (JAKi experienced; MMB vs best available therapy), and MOMENTUM (JAKi experienced; MMB vs danazol). The EQ-5D-5L was administered, and health state index (UK value set) and visual analog scale (VAS) scores derived, in all 3 trials. Patient Global Impression of Change (PGIC) was administered in S1/S2. Hb improvement was defined as an increase of ≥1, ≥1.5, or ≥2 g/dL from BL at wk 24. Multivariate (MV) analyses included change in EQ-5D-5L scores from BL as the dependent variable, with wk 24 Hb improvement and key BL characteristics as independent variables. Results: Mean age of the anemic subpopulation (N=480) was 68.8 y; 62% were male, 81% were White, and 64% had primary MF.436 pts were evaluable for Hb improvement at wk 24; 298 and 297 were evaluable for EQ-5D-5L index and VAS scores, respectively. Mean improvements from BL in index and VAS scores were greater in pts who achieved Hb improvement at any threshold than in those who did not (Table). 241 pts were evaluable for Hb improvement at wk 24 in S1/S2; 215 were evaluable for PGIC. Hb improvement was associated with a higher percentage of pts with any symptom improvement and lower percentage with symptom worsening based on PGIC (Table). In MV analyses, Hb improvement at any threshold was significantly associated with positive change in EQ-5D-5L VAS scores at wk 24 (mean change estimates of 5.5 to 7.3); similar trends were observed in MV analyses for EQ-5D-5L index scores. Conclusions: In these trial populations, Hb improvement at wk 24 was associated with improved HRQOL and symptoms in pts with MF and anemia. These results highlight the value of treatments with anemia-related benefits in improving the pt experience in MF. Clinical trial information: NCT04173494 ; NCT02101268 ; NCT01969838 . [Table: see text]
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
Kumar, Anita , Hill, Brian T. , Danilov, Alexey V. , Pongas, Georgios , Greenwell, Irl Brian , Cohen, Jonathon B. , Martin, Peter , Wang, Yucai , Larson, Melissa C. , Bond, David A. , Kahl, Brad S. , Merryman, Reid W. , Grover, Natalie S. , Tun, Aung M. , Ayyappan, Sabarish Ram , Portell, Craig A. , Muñoz, Javier , Reagan, Patrick Michael , Moustafa, Muhamad Alhaj , Pophali, Priyanka A.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7006-7006

10.1200/jco.2024.42.16_suppl.7006 Get It

7006 Background: Rituximab maintenance (RM) after first-line (1L) bendamustine and rituximab (BR) in MCL did not improve progression-free survival in the MAINTAIN trial (Rummel et al, ASCO 2016) but was associated with improved survival outcomes in a North American observational study (Martin et al, JCO 2023). We sought to examine the potential benefit of RM after BR using a large observational cohort from 26 US academic centers. Methods: Patients with MCL who received 1L BR (without stem cell transplant) outside of clinical trials were included. At the landmark of 3 months after the end of BR, patients who achieved a complete response (CR) or partial response (PR) to BR and had no evidence of progressive disease (PD) or second-line (2L) therapy were deemed eligible for RM. Event-free survival (EFS) was defined as time from landmark to progression, relapse, retreatment, or death. EFS2 was defined as time from landmark to progression, relapse, or retreatment following 2L therapy or death. RM was not considered a line of therapy for either endpoint. OS was defined as time from landmark to death. Survival analysis was done with Kaplan-Meier methods and Cox regression models adjusting for sex and simplified MIPI. Results: Among 796 patients who received 1L BR in 2007-2020, 693 achieved a CR or PR. At the 3-month post-BR landmark, 613 had no evidence of PD, among whom 318 (52%) received RM and 295 did not. The RM group was younger (median age 70 vs 72, p = 0.010) and more predominantly male (78% vs 69%, p = 0.047). There was no statistical difference in stage, simplified MIPI, histology (blastoid or pleomorphic vs classic), Ki-67, TP53 alteration, complex karyotype, year of BR start, or best response to BR between the two groups. The median follow-up after the 3-month post-BR landmark was 61.3 months (95% CI 62.6-70.4). The median number of doses of RM was 10 (IQR 5-12). RM was associated with improved EFS (median 47.1 vs 29.7 months, adjusted HR 0.59, 95% CI 0.48-0.73), EFS2 (median 89.1 vs 48.3 months, adjusted HR 0.63, 95% CI 0.50-0.81), and OS (median 136.1 vs 74.3 months, adjusted HR 0.57, 95% CI 0.44-0.75) (all p values < 0.001). In patients with CR to 1L BR (n=527), 271 (51%) received RM, for a median of 11 (IQR 6-12) doses. In this subgroup, RM was associated with improved EFS (median 60.6 vs 31.5 months, adjusted HR 0.56, 95% CI 0.44-0.71), EFS2 (median 89.1 vs 48.3 months, adjusted HR 0.62, 95% CI 0.48-0.81), and OS (median 136.1 vs 75.6 months, adjusted HR 0.59, 95% CI 0.44-0.79) (all p values < 0.001). Analysis in patients with PR to 1L BR was limited by the sample size (n=86, 47 received RM). The numeric differences in median EFS (20.8 vs 11.5, log-rank p = 0.370), EFS2 (48.9 vs 30.3, log-rank p = 0.210) and OS (87.3 vs 46.9, log-rank p = 0.067) were not statistically significant. Conclusions: In this large multicenter study, RM after 1L BR was associated with improved EFS and OS, supporting its use in routine practice for patients with newly diagnosed MCL.
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH -wild type and -mutant lower grade gliomas
Roy, Soumyajit , Brown, Paul D. , DeStephano, David, Canoll, Peter , Qureshi, Summer S., Gallito, Matthew, Sisti, Michael B. , Bruce, Jeffrey N. , Horowitz, David P. , Kachnic, Lisa A. , Neugut, Alfred I. , Cheng, Simon K. , Wang, Tony J. C. , Kinslow, Connor J , Bruce, Jeffrey N , Wang, Tony J C , IWAMOTO, FABIO MASSAITI , Gallito, Matthew, Yu, James B. , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | June 28, 2024 | Volume: 26 | Issue: 10 | Pages: 1839-1849

10.1093/neuonc/noae102 | PMID 38943513 Get It

Abstract Background IDH-wild type (-wt) status is a prerequisite for the diagnosis of glioblastoma (GBM); however, IDH-wt gliomas with low-grade or anaplastic morphology have historically been excluded from GBM trials and may represent a distinct prognostic entity. While alkylating agent chemotherapy improves overall survival (OS) and progression-free survival (PFS) for IDH-wt GBM and also IDH-mutant gliomas, irrespective of grade, the benefit for IDH-wt diffuse histologic lower-grade gliomas is unclear. Methods We performed a meta-analysis of randomized clinical trials for World Health Organization (WHO) grades 2–3 gliomas (2009 to present) to determine the effect of alkylating chemotherapy on IDH-wt and -mutant gliomas using a random-effects model with inverse-variance pooling. Results We identified 6 trials with 1204 patients (430 IDH-wt, 774 IDH-mutant) that evaluated alkylating chemoradiotherapy versus radiotherapy alone, allowing us to perform an analysis focused on the value of adding alkylating chemotherapy to radiotherapy. For patients with IDH-wt tumors, alkylating chemotherapy added to radiotherapy was associated with improved PFS (HR:0.77 [95% CI: 0.62–0.97], P = .03) but not OS (HR:0.87 [95% CI: 0.64–1.18], P = .17). For patients with IDH-mutant tumors, alkylating chemotherapy added to radiotherapy improved both OS (HR:0.52 [95% CI: 0.42–0.64], P &lt; .001) and PFS (HR = 0.47 [95% CI: 0.39–0.57], P &lt; .001) compared to radiotherapy alone. The magnitude of benefit was similar for IDH-mutant gliomas with or without 1p19q-codeletion. Conclusions Alkylating chemotherapy reduces mortality by 48% and progression by 53% for patients with IDH-mutant gliomas. Optimal management of IDH-wt diffuse histologic lower-grade gliomas remains to be determined, as there is little evidence supporting an OS benefit from alkylating chemotherapy.
Real‐world evaluation of interconsensus agreement of risk of bias tools: A case study using risk of bias in nonrandomized studies‐of interventions (ROBINS‐I)
Saadi, Samer , Kanaan, Adel, Abusalih, Mohamed , Tarakji, Zin, Sadek, Mustafa , Basha, Ayla Shamsi , Hasan, Bashar , Shamsi Basha, Ayla, Saadi, Samer , Abusalih, Mohamed , Hasan, Bashar , Firwana, Mohammed , Wang, Zhen , Murad, M. Hassan

Mayo Clinic

Cochrane Evidence Synthesis and Methods | June 26, 2024 | Volume: 2 | Issue: 7 | Pages: No page available

10.1002/cesm.12094 | PMID 40475320 Get It

Abstract Background Risk of bias (RoB) tools are critical in systematic reviews and affect subsequent decision‐making. RoB tools should have adequate interrater reliability and interconsensus agreement. We present an approach of post hoc evaluation of RoB tools using duplicated studies that overlap systematic reviews. Methods Using a back‐citation approach, we identified systematic reviews that used the Risk Of Bias In Nonrandomized Studies‐of Interventions (ROBINS‐I) tool and retrieved all the included primary studies. We selected studies that were appraised by more than one systematic review and calculated observed agreement and unweighted kappa comparing the different systematic reviews' assessments. Results We identified 903 systematic reviews that used the tool with 51,676 cited references, from which we eventually analyzed 171 duplicated studies assessed using ROBINS‐I by different systematic reviewers. The observed agreement on ROBINS‐I domains ranged from 54.9% (missing data domain) to 70.3% (deviations from intended interventions domain), and was 63.0% for overall RoB assessment of the study. Kappa coefficient ranged from 0.131 (measurement of outcome domain) to 0.396 (domains of confounding and deviations from intended interventions), and was 0.404 for overall RoB assessment of the study. Conclusion A post hoc evaluation of RoB tools is feasible by focusing on duplicated studies that overlap systematic review. ROBINS‐I assessments demonstrated considerable variation in interconsensus agreement among various systematic reviewes that assessed the same study and outcome, suggesting the need for more intensive upfront work to calibrate systematic reviewers on how to identify context‐specific information and agree on how to judge it.